SmartFuture launches SDK to enable plug-and-play Remote Patient Monitoring in existing healthcare payer and provider applications
SINGAPORE, Dec. 7, 2022 /PRNewswire/ -- SmartFuture, a leading health-tech company and provider of integrated RPM (Remote Patient Monitoring) solutions, has launched an RPM SDK (Software Development Kit) product. SmartFuture's RPM SDK product allows healthcare providers and payers to integrate white-labelled remote patient monitoring functionality inside their existing apps and web portals in a plug-and-play manner to boost patient engagement...
Veeva Pulse Shows Digitally Enabled Field Teams are Using HCP Time More Effectively in Asia Pacific
HCP Access is selective as nearly half meet with only one company monthly SINGAPORE, Dec. 7, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced findings from the latest Veeva Pulse Field Trends Report, the largest global industry benchmark of its kind on healthcare professional HCP engagement. Asia Pacific data shows that...
Suvoda Launches eCOA-Specific Language and Design Toolkit as Solution Moves to Second Phase of Early Adopter Program
Practical, innovative functionality seeks to alleviate eCOA burdens, reduce time-to-launch, and improve site, clinician, and patient experience. PHILADELPHIA, Dec. 7, 2022 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas such as oncology, central nervous system (CNS), and rare disease, today announced that...
Parnell Pharmaceuticals Holdings Ltd Announces Commencement of Rights Offering
SYDNEY, Dec. 7, 2022 /PRNewswire/ -- Parnell Pharmaceuticals Holdings Ltd (OTC Pink® Open Market: PARNF) ("Parnell") today commenced its previously announced backstopped rights offering to raise gross proceeds of approximately US$4.0 million (the "Rights Offering"). Under the terms of the Rights Offering, at no charge, the qualifying shareholders as of 5:00 PM (Eastern Time), on December 6, 2022 (the...
New International Consensus on CGM Clinical Trial Metrics Aims to Spur Diabetes Treatment Advances
SAN FRANCISCO, Dec. 7, 2022 /PRNewswire/ -- The diaTribe Foundation, Advanced Technologies & Treatments for Diabetes (ATTD), and the Time in Range Coalition announced today a new international consensus regarding continuous glucose monitoring (CGM) metrics for clinical trials to help accelerate the development of new and improved treatments for people living with...
Healthcare Summit Convened to Address Maternal-Fetal Outcomes in Sub-Saharan Africa
ROCKVILLE, Md., Dec. 6, 2022 /PRNewswire/ -- Inteleos, a non-profit global healthcare certification organization and Kenya Healthcare Federation, a membership-based organization that serves as the umbrella body for Kenya's Private Health Sector, hosted a maternal and fetal ultrasound summit on Nov. 9 and 10, at the Radisson Hotel Blu Upper Hill, in Nairobi, Kenya. The summit brought together key stakeholders...
Turn Biotechnologies Changes Paradigm in Skin Rejuvenation
Data unveiled at four industry conferences suggest a single ERA treatment may be more effective than combination therapies used today Biomarker analysis demonstrates ERA's regenerative impact on fibroblast proliferation, collagen VII production eTurna™ lipid-based delivery platform proves groundbreakingly effective at reaching targeted tissue Company to present updated data during...
Newtown’s Apple to Highly Saturated Global Molecular Market, TIANGEN TGuide S16 Automated Nucleic Acid Extractor Showcased at Cell Bio 2022
WASHINGTON, Dec. 6, 2022 /PRNewswire/ -- TIANGEN, a high-tech biological enterprise, demonstrated its revolutionary nucleic acid extraction solution at Cell Bio 2022, the joint meeting of the American Society for Cell Biology (ASCB) and European Molecular Biology Organization (EMBO), from Dec 4 to 6. Eye-catching as it is, the smart automated extractor hit the great potential need of...
Akeso Inc. Announces Collaboration and License Agreement for Up to US$5 Billion with Summit Therapeutics to Accelerate Global Development and Commercialization of its Breakthrough Bispecific Antibody, Ivonescimab (PD-1/VEGF)
Akeso Inc. to out-license to Summit Therapeutics exclusive rights to ivonescimab (PD-1/VEGF) for the development and commercialization in the United States, Canada, Europe, and Japan. Akeso Inc. will retain development and commercialization rights for the rest of the world including China. Akeso Inc. to receive US$500 million upfront payment and the...
CORVIA MEDICAL ANNOUNCES RANDOMIZATION OF FIRST PATIENT IN THE RESPONDER-HF CONFIRMATORY TRIAL
Corvia® Atrial Shunt has the potential to change the way heart failure is treated TEWKSBURY, Mass., Dec. 6, 2022 /PRNewswire/ -- Corvia Medical, Inc., a company dedicated to transforming the treatment of heart failure (HF), announced the first patient has been randomized in RESPONDER-HF, a global confirmatory trial of the Corvia...
